Rapid Fire 1

Moderator

Namita Chittoria

Moderator

Hikmat Abdel-Razeq, King Hussein Cancer Center, Amman, Jordan

Presentation numberRF1-1

Zanidatamab as a component of neoadjuvant therapy in HER2+ breast cancer: results from the I-SPY2.2 trial

Anthony D Elias, University of Colorado, Aurora, CO

Presentation numberRF1-2

Event-free survival from the randomized phase 2 neohip trial evaluating neoadjuvant taxane, her2-targeted therapy, +/- pembrolizumab in early-stage her2-positive breast cancer

Heather L McArthur, UTSW, Dallas, TX

Presentation numberRF1-3

Circulating tumor DNA (ctDNA) dynamics and pathological complete response (pCR) in high-risk HER2+ early breast cancer (eBC) treated with neoadjuvant trastuzumab deruxtecan followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP): A DESTINY-Breast11 (DB-11) analysis

Shanu Modi, Memorial Sloan Kettering Cancer Center, New York, NY

Presentation numberRF1-4

Optimising the duration of trastuzumab in early-stage HER2-positive breast cancer – an Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis

Rosie Bradley, University of Oxford, Oxford, United Kingdom

Presentation numberRF1-5

A randomized trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: First analysis of the ARIADNE trial

Theodoros Foukakis, Karolinska Institute, Stockholm, Sweden

Presentation numberRF1-6

Patina (aft-38): palbociclib benefit across key prespecified subgroups in hr+/her2-positive advanced breast cancer – final protocol-specified pfs analysis

Otto Metzger, Dana-Farber Cancer Institute, Boston, MA

Presentation numberRF1-7

The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab – Outcomes in Patients with HER2+ Metastatic Breast Cancer (MBC) (TBCRC 062)

Heather A Parsons, Fred Hutchinson Cancer Center, Seattle, WA